Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.39 |
| ▸ | CNR1 | P21554 | 7/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.34 |
| ▸ | PPARD | Q03181 | 2/20 | 0.34 |
| ▸ | PPARA | Q07869 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10300851 | 1.00 | CNR2 (0.39) | CNR2CNR1TRPA1TRPV1SOAT1 | |
| SCHEMBL10300839 | 0.80 | SOAT1 (0.42) | CNR2CNR1TRPA1TRPV1SOAT1 | |
| SCHEMBL4888294 | 0.76 | TSHR (0.48) | CNR2CNR1TRPA1TRPV1SOAT1 | |
| SCHEMBL4888284 | 0.76 | TSHR (0.48) | CNR2CNR1TRPA1TRPV1SOAT1 | |
| SCHEMBL11029452 | 0.76 | CNR2 (0.44) | CNR2CNR1TRPA1TRPV1SOAT1 | |
| SCHEMBL11029451 | 0.76 | CNR2 (0.44) | CNR2CNR1TRPA1TRPV1SOAT1 | |
| SCHEMBL2683632 | 0.73 | NR1I2 (0.46) | CNR2CNR1TRPA1TRPV1SOAT1 | |
| SCHEMBL10300850 | 0.73 | NR1I2 (0.46) | CNR2CNR1TRPA1TRPV1SOAT1 | |
| SCHEMBL2683633 | 0.73 | NR1I2 (0.46) | CNR2CNR1TRPA1TRPV1SOAT1 | |
| SCHEMBL18126434 | 0.71 | TSHR (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029593-B2 | Method for manufacturing spilanthol and intermediate manufacturing product therefor | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-05-12 | — | — | US | disclosed |
| US-9029593-B2 | Method for manufacturing spilanthol and intermediate manufacturing product therefor | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-05-12 | — | — | US | disclosed |
| US-20120116116-A1 | METHOD FOR MANUFACTURING SPILANTHOL AND INTERMEDIATE MANUFACTURING PRODUCT THEREFOR | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-05-10 | — | — | US | disclosed |
| US-20120116116-A1 | METHOD FOR MANUFACTURING SPILANTHOL AND INTERMEDIATE MANUFACTURING PRODUCT THEREFOR | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116116-A1 | METHOD FOR MANUFACTURING SPILANTHOL AND INTERMEDIATE MANUFACTURING PRODUCT THEREFOR | CYP4A11, CYP4F8, CYP51A1 | CNR2 522/4885CNR1 363/4885TRPA1 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.